Marinus Pharmaceuticals
Mar 12, 2015

Marinus Pharmaceuticals Provides Business Update and Reports Year End 2014 Financial Results

RADNOR, Pa., March 12, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric therapeutics, today provided a business update and announced its financial results for the year ended December 31, 2014.

"2014 was a great year for Marinus," commented Christopher M. Cashman, Chairman and CEO of Marinus Pharmaceuticals. "We expanded and accelerated the clinical development of ganaxolone, our novel synthetic analog of the endogenous neurosteroid allopregnanolone, in several important indications. In addition to moving ganaxolone into a Phase 3 trial in adults with focal onset seizures and into a Phase 2 trial in the orphan indication of PCDH19 female pediatric epilepsy, we are progressing with the pre-clinical development of ganaxolone IV to ready it for the clinic. Over the next twelve months, we anticipate having data from several of our ongoing programs."

Pipeline Highlights

Ganaxolone in Epilepsy

Ganaxolone in Fragile X Syndrome (FXS)

Financial Update

Marinus reported net losses of $10.8 million and $5.3 million for the years ended December 31, 2014 and 2013, respectively. Cash used in operating activities was $8.6 million for the year ended December 31, 2014 compared to $6.6 million for the same period a year ago.

Research and development expenses increased by $4.5 million, to $8.7 million, for the year ended December 31, 2014, compared to the same period of 2013. The increase was primarily due to the increase in clinical costs related to our ongoing clinical trial of ganaxolone in patients with focal onset seizures that commenced at the end of 2013. Substantially all research and development expenses relate to our clinical trial in focal onset epileptic seizures.

General and administrative expenses increased by $2.0 million, to $3.2 million, for the year ended December 31, 2014, compared to the same period of 2013. The increase in general and administrative expenses was primarily due to the hiring of new management and the upward scaling of our operations in connection with both our new public company status and ongoing clinical trial of ganaxolone in patients with focal onset seizures that commenced during 2013.

At December 31, 2014, the Company had cash and cash equivalents of $49.7 million, compared to $10.0 million at December 31, 2013. The increase was primarily due to $41.2 million in net proceeds received in 2014 from the closing of our initial public offering and $7.0 million in net proceeds received in 2014 related to our credit facility with Square 1 Bank, offset by $8.6 million in cash used in operating activities.

Readers are referred to, and encouraged to read in their entirety, the Forms 8-K regarding the matters referred to herein, including any exhibits attached thereto, and the Company's Annual Report on Form 10-K for the year ended December 31, 2014 to be filed with the Securities and Exchange Commission, which includes further detail on the above-referenced transactions and the Company's business plans and operations, financial condition and results of operations.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate for the treatment of seizure disorders in adults and children with epilepsy is ganaxolone. Ganaxolone is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone (known for its anticonvulsive and antianxiety effects) and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. The Company is currently conducting a multi-national, randomized, placebo-controlled, Phase 3 clinical trial to evaluate ganaxolone as adjunctive treatment of partial-onset seizures in adults. Ganaxolone is also being studied in a Phase 2 proof-of-concept clinical study for the treatment of the rare, genetic disorder, PCDH19 female pediatric epilepsy. To complement the existing formulations and to provide continuity of care, the Company is developing an IV formulation of ganaxolone for use in the hospital setting to control epileptic seizures. In addition, ganaxolone is being evaluated in a Phase 2 proof-of-concept investigator-sponsored clinical trial as a treatment for behaviors in FXS. For additional information, please visit the Company's website at

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Words such as "may", "will", "expect", "anticipate", "estimate", "intend", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.  Examples of forward looking statements contained in this press release include, among others, statements regarding our expectations regarding our development plans for our product candidate, including, potential for orphan designation, optimizing a product's formulation, the clinical trial testing schedule, timing for availability and release of data, the safety, potential efficacy and therapeutic potential of our product candidate and our expectation regarding the sufficiency of our working capital. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.  Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical trials, the timing of the clinical trials, enrollment in clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters, including the development of formulations of ganaxolone, that could affect the availability or commercial potential of our drug candidates. Marinus undertakes no obligation to update or revise any forward-looking statements.  For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission. 

Marinus Pharmaceuticals, Inc.
Selected Financial Data (in thousands, except share and per share amounts)
 December 31,
Cash and cash equivalents  $ 49,720  $ 10,037
Other assets 493 1,787
Total assets  $ 50,213  $ 11,824
Total current liabilities 2,039 2,366
Notes payable 7,000
Other long term liabilities 20
Total liabilities 9,059 2,366
Total stockholders' equity (deficit) 41,154 (60,381)
Total liabilities and stockholders' equity (deficit)  $ 50,213  $ 11,824
 Year Ended December 31,
Research and development $ 8,690 $ 4,150
General and administrative 3,230 1,229
Loss from operations (11,920) (5,379)
Change in fair value of warrant liability 1,192 153
Interest income 12 47
Interest expense (117) (91)
Net loss (10,833) (5,270)
Cumulative preferred stock dividends (2,545) (3,804)
Net loss applicable to common stockholders  $ (13,378)  $ (9,074)
Per share information:    
Net loss per share of common stock—basic and diluted  $ (2.17)  $ (19.60)
Basic and diluted weighted average shares outstanding 6,152,669 462,972
CONTACT: Company:

         Lisa M. Caperelli

         Senior Director, Investor Relations & Corporate Communications

         Marinus Pharmaceuticals, Inc.



         Media Contact:

         Tiberend Strategic Advisors, Inc.

         Amy S. Wheeler